Effectiveness of Palivizumab in Preventing RSV Hospitalization in High Risk Children: A Real-World Perspective
Infection with respiratory syncytial virus (RSV) is one of the major causes globally of childhood respiratory morbidity and hospitalization. Palivizumab, a humanized monoclonal antibody, has been recommended for high risk infants to prevent severe RSV-associated respiratory illness. This recommendat...
Saved in:
Main Authors: | Nusrat Homaira, William Rawlinson, Thomas L. Snelling, Adam Jaffe |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2014-01-01
|
Series: | International Journal of Pediatrics |
Online Access: | http://dx.doi.org/10.1155/2014/571609 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
The Real-Life Effectiveness of Palivizumab for Reducing Hospital Admissions for Respiratory Syncytial Virus in Infants Residing in Nunavut
by: Anna Banerji, et al.
Published: (2014-01-01) -
Leveraging Real-World Evidence to Define Severe RSV Lower Respiratory Tract Disease in Adults
by: Catherine A. Panozzo, et al.
Published: (2024-11-01) -
Respiratory Syncytial Virus and Palivizumab: Where are We in 2014?
by: Joan Robinson
Published: (2014-01-01) -
The Use of Albuterol in Young Infants Hospitalized with Acute RSV Bronchiolitis
by: Michael T. Del Vecchio, et al.
Published: (2012-01-01) -
Relationship between RSV-hospitalized children and meteorological factors: a time series analysis from 2017 to 2023
by: Shuying Wang, et al.
Published: (2025-02-01)